Xenon reported a Q4 net loss of USD 105.3 million and a FY 2025 net loss of USD 345.9 million. Q4 R&D expenses were USD 87.7 million and G&A expenses were USD 22.1 million, while FY 2025 R&D expenses were USD 300.9 million and G&A expenses were USD 79.6 million. Other income totaled USD 5.0 million in Q4 and USD 28.2 million for FY 2025. Xenon recorded FY 2025 revenue of USD 7.5 million. Cash, cash equivalents and marketable securities were USD 586.0 million as of Dec. 31, 2025, and pro forma cash was USD 716.0 million including USD 130.0 million of Q1 2026 ATM proceeds; the company said this extends its cash runway into H2 2027. On the business side, Xenon said Phase 3 X-TOLE2 topline data for azetukalner in focal onset seizures are expected in the first half of March 2026, with an anticipated NDA submission in H2 2026. Additional Phase 3 studies of azetukalner continue to enroll across epilepsy and neuropsychiatry, including X-NOVA2 in major depressive disorder with topline data expected in H1 2027. In early-stage R&D, Phase 1 studies of pain candidates XEN1701 (NaV1.7) and XEN1120 (KV7) are underway, with data expected in 2026 to support Phase 2 proof-of-concept studies. Xenon also highlighted long-term open-label extension data showing over 90% reductions in monthly focal onset seizure frequency among participants treated for ≥48 months and over 38% achieving at least 12 months of seizure freedom.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602261601PRIMZONEFULLFEED9662264) on February 26, 2026, and is solely responsible for the information contained therein.
Comments